In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Quantitative techniques based on real-time PCR have been available for leukemia diagnostics for a relatively long time; other innovative methods of molecular quantification are available ...

Syndax Pharmaceuticals (NASDAQ:SNDX) fell ~23% in the premarket on Tuesday after the cancer drug developer reported topline data from a pivotal Phase 2 portion of its AUGMENT-101 trial for revumenib, ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia, or ...

NBC News was first among them. Weinstein, 72, has chronic myeloid leukemia and is undergoing treatment behind bars in Rikers Island, the reports say, citing sources. He underwent emergency heart ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...

Roughly 15% to 30% of people with CML go on to develop acute myeloid leukemia. CML also typically affects more men than women, it says. Last month, Weinstein underwent emergency heart surgery.